IPG Photonics Corporation — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020; compared with the three months ended March 31, 2019 unless otherwise noted. IPG develops and sells fiber lasers, amplifiers, diode lasers and related systems, primarily for materials processing. The unaudited interim results reflect the early effects of COVID-19.
Financial results
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Net sales | $249.2 million | $315.0 million | Down 20.9% |
| Gross profit / margin | $102.9 million / 41.3% | $148.9 million / 47.3% | Margin down 6.0 percentage points |
| Operating income | $44.8 million | $68.3 million | Down 34.4% |
| Net income attributable to IPG | $36.4 million | $55.2 million | Down 34.0% |
| Diluted EPS | $0.68 | $1.02 | Down 33.3% |
| Operating cash flow | $56.8 million | $43.7 million | Up $13.1 million |
- Sales from materials processing, 87.5% of quarterly revenue, fell 27.6% to $218.1 million. Other-application sales rose 123.2% to $31.2 million. China sales were $68.6 million versus $114.4 million, a 40% decline, according to management.
- High-power CW laser sales fell 33.4%; laser and non-laser systems fell 42.9%. Other revenue, including amplifiers, service, parts and accessories, rose 38.2%; pulsed laser sales rose 1.3%.
- Gross margin was pressured by lower sales, greater inventory provisions ($8.5 million versus $4.8 million) and lower absorption of manufacturing costs. Operating expenses were broadly flat in dollars, but higher as a share of sales.
- A $19.6 million foreign-exchange gain, primarily related to ruble and euro depreciation, supported operating results; Q1 2019 included a $1.6 million FX loss. Foreign-currency translation produced a $73.4 million other comprehensive loss.
- Cash and cash equivalents were $570.1 million and short-term investments were $625.1 million at March 31, 2020, totaling $1.20 billion. Total debt was $40.8 million; no amounts were drawn on the disclosed credit facilities. Unused lines and overdraft facilities totaled $129.2 million. The company reported compliance with debt covenants.
- Operating cash flow improved despite lower earnings, mainly due to working-capital movements. Investing cash outflow was $139.8 million, including $122.2 million of net short-term investment purchases and $17.8 million of capital expenditures. Financing cash outflow was $20.8 million, including $12.7 million of treasury-stock purchases.
Management commentary, outlook and risks
- COVID-19 reduced demand, first most notably in Asia; effects began later in the quarter in Europe and North America. China orders rebounded in late March and April, while bookings declined in other regions. Management said global recovery visibility was uncertain and it could not reasonably estimate the pandemic’s future financial effects.
- Facilities in the U.S., Germany and Russia remained open, though U.S. production was scaled back to comply with government orders. Safety measures affected productivity; logistics constraints included limited air cargo capacity, higher freight rates and border delays. Management warned prolonged disruption could adversely affect revenue, profitability, cash flow and inventory or credit-loss provisions, and could trigger asset impairments.
- Management expected approximately $115 million to $125 million of 2020 capital expenditures, excluding acquisitions. It believed cash, investments, expected operating cash flows and available credit facilities would cover working-capital and operating needs for the next 12 months, while noting spending plans could be adjusted.
- Other significant exposures include competition and pricing pressure, cyclical capital-equipment spending, customer concentration (five largest customers represented 21% of Q1 sales), foreign-exchange volatility, and potential goodwill or long-lived-asset impairments. One customer represented 23% of receivables at quarter-end.
- Subsequent events: the German revolving credit facility was extended to July 2023. On May 5, 2020, the board authorized an additional $200 million share repurchase program; together with the existing authorization, the filing described a total program of up to $260 million. Authorizations do not require purchases.
Important facts for investors to verify
- Whether post-quarter bookings and demand recover across regions, and how COVID-19 restrictions affect production, logistics and customers.
- Whether revenue, product mix, pricing and manufacturing utilization stabilize enough to recover gross margin.
- Whether inventory provisions, customer payment delays or currency movements materially affect future earnings and cash flow.
- Whether planned capital spending and share repurchases remain consistent with liquidity and operating needs.
- Whether pandemic-related developments trigger impairment testing or charges; no COVID-19-related impairment charge was recorded in Q1.